Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
PurposeWe aimed to investigate the restoration of CD8+PD-1+ T cells through adoptive T-cell therapy (ACT) in relation to the prognosis and the therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC).MethodsA total of 177 adult patients who underwent tumor resection as ini...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.837560/full |
| _version_ | 1819022729922215936 |
|---|---|
| author | Qian Zhu Guoliang Qiao Lefu Huang Chang Xu Deliang Guo Shuo Wang Shuo Wang Jing Zhao Yuguang Song Bing Liu Zheng Chen Zhiyong Yang Yufeng Yuan |
| author_facet | Qian Zhu Guoliang Qiao Lefu Huang Chang Xu Deliang Guo Shuo Wang Shuo Wang Jing Zhao Yuguang Song Bing Liu Zheng Chen Zhiyong Yang Yufeng Yuan |
| author_sort | Qian Zhu |
| collection | DOAJ |
| description | PurposeWe aimed to investigate the restoration of CD8+PD-1+ T cells through adoptive T-cell therapy (ACT) in relation to the prognosis and the therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC).MethodsA total of 177 adult patients who underwent tumor resection as initial treatment for pancreatic ductal adenocarcinoma (PDAC) from February 2013 to July 2019 at Zhongnan Hospital of Wuhan University were enrolled in this study. Another cohort of 32 patients with APC was prospectively enrolled from Capital Medical University Cancer Center between June 1, 2013, and May 30, 2019.ResultsOf the 177 patients who received tumor resection, 67 tumor samples showed overexpression of PD-L1 and 110 patients with low expression of PD-L1. We found that overexpressed PD-L1 was a significant prognostic factor related to overall survival (OS). Furthermore, we tested the percentage of peripheral CD8+PD-1+ T cells in all patients and found that it was significantly correlated with the PD-L1 expression and the prognosis of patients with PDAC. The peripheral blood T lymphocyte subtypes were tracked for 30 months, and CD8+PD-1+ cells were shown to decrease. After that, we performed ACT for patients with APC in another cancer center. We found that the ratios of posttreatment of ACT/pre-ACT CD8+PD-1+ T cells were significantly related to the prognosis of patients with APC. Moreover, patients with combined treatment of ACT with anti-PD-1 had significantly favorable OS.ConclusionsThis study showed that the CD8+PD-1+ T-cell level was related to the expression of PD-L1. Restoring CD8+PD-1+ T cells in patients with APC by treatment of ACT significantly benefits the prognosis and facilitates the response to anti-PD-1. |
| first_indexed | 2024-12-21T04:27:38Z |
| format | Article |
| id | doaj.art-9376d8b97b8e4d908329f5c8bd46033c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T04:27:38Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9376d8b97b8e4d908329f5c8bd46033c2022-12-21T19:16:01ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.837560837560Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal AdenocarcinomaQian Zhu0Guoliang Qiao1Lefu Huang2Chang Xu3Deliang Guo4Shuo Wang5Shuo Wang6Jing Zhao7Yuguang Song8Bing Liu9Zheng Chen10Zhiyong Yang11Yufeng Yuan12Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Surgical Oncology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaFirst Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of General Surgery, Chinese People’s Liberation Army General Hospital, Beijing, ChinaDepartment of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaDepartment of General Surgery, Huo Jianjun General Hospital, Beijing, ChinaDepartment of General Surgery, Capital Institute of Pediatrics, Beijing, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, ChinaPurposeWe aimed to investigate the restoration of CD8+PD-1+ T cells through adoptive T-cell therapy (ACT) in relation to the prognosis and the therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC).MethodsA total of 177 adult patients who underwent tumor resection as initial treatment for pancreatic ductal adenocarcinoma (PDAC) from February 2013 to July 2019 at Zhongnan Hospital of Wuhan University were enrolled in this study. Another cohort of 32 patients with APC was prospectively enrolled from Capital Medical University Cancer Center between June 1, 2013, and May 30, 2019.ResultsOf the 177 patients who received tumor resection, 67 tumor samples showed overexpression of PD-L1 and 110 patients with low expression of PD-L1. We found that overexpressed PD-L1 was a significant prognostic factor related to overall survival (OS). Furthermore, we tested the percentage of peripheral CD8+PD-1+ T cells in all patients and found that it was significantly correlated with the PD-L1 expression and the prognosis of patients with PDAC. The peripheral blood T lymphocyte subtypes were tracked for 30 months, and CD8+PD-1+ cells were shown to decrease. After that, we performed ACT for patients with APC in another cancer center. We found that the ratios of posttreatment of ACT/pre-ACT CD8+PD-1+ T cells were significantly related to the prognosis of patients with APC. Moreover, patients with combined treatment of ACT with anti-PD-1 had significantly favorable OS.ConclusionsThis study showed that the CD8+PD-1+ T-cell level was related to the expression of PD-L1. Restoring CD8+PD-1+ T cells in patients with APC by treatment of ACT significantly benefits the prognosis and facilitates the response to anti-PD-1.https://www.frontiersin.org/articles/10.3389/fonc.2022.837560/fullCD8+PD-1+ T cellTCRPDACtumor resectionadoptive cell immunotherapy |
| spellingShingle | Qian Zhu Guoliang Qiao Lefu Huang Chang Xu Deliang Guo Shuo Wang Shuo Wang Jing Zhao Yuguang Song Bing Liu Zheng Chen Zhiyong Yang Yufeng Yuan Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma Frontiers in Oncology CD8+PD-1+ T cell TCR PDAC tumor resection adoptive cell immunotherapy |
| title | Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma |
| title_full | Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma |
| title_fullStr | Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma |
| title_short | Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma |
| title_sort | restored cd8 pd 1 t cells facilitate the response to anti pd 1 for patients with pancreatic ductal adenocarcinoma |
| topic | CD8+PD-1+ T cell TCR PDAC tumor resection adoptive cell immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.837560/full |
| work_keys_str_mv | AT qianzhu restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT guoliangqiao restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT lefuhuang restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT changxu restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT deliangguo restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT shuowang restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT shuowang restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT jingzhao restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT yuguangsong restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT bingliu restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT zhengchen restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT zhiyongyang restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma AT yufengyuan restoredcd8pd1tcellsfacilitatetheresponsetoantipd1forpatientswithpancreaticductaladenocarcinoma |